Drugmaker Eli Lilly said that in Phase 3 studies of over 550 adults, their oral GLP-1 pill, orforglipron, could reduce ...

Shares jumped 16% as results of the study, the first of several underway on the pill, orforglipron, raised hopes of an effective and easy-to-use treatment reaching a market dominated by weight ...

The study is the first of several under way on the pill, orforglipron, and raised hopes of an effective and easy-to-use treatment reaching a market dominated by weight-loss ... of 4.7 per cent ...

Diabetics given the pill called orforglipron lost 16 pounds, or 7.9% of their body weight ... are still working on their own weight-loss pills, with varying degrees of success.

Novo's U.S.-listed shares fell 7%, after Jefferies said the Lilly pill looks competitive with Novo's injectable Ozempic in diabetes, and shows weight loss that looks to be in line with Novo's ...

Shares of Eli Lilly soared Thursday morning after the pharmaceutical giant announced a clinical trial of its once-daily weight loss pill, orforglipron, demonstrated effectiveness consistent with ...

The highest dose of the pill helped patients lose 7.9% of their weight, or around 16 pounds, on average after 40 weeks. Eli Lilly also said patients saw no plateau in their weight loss by the time ...